Assessment of ALK status by FISH on 1000 Spanish non-small cell lung cancer patients

Journal of Thoracic Oncology

Volumn 9, Issue 12, 2014, Pages 1816-1820

  Vidal, Joana ^a   Clavé, Sergi ^a   De Muga, Silvia ^a,b   González, Iria ^a   Pijuan, Lara ^a   Gimeno, Javier ^a   Remón, Jordi ^c   Reguart, Noemí ^d   Viñolas, Nuria ^d   Gironés, Regina ^e   Bernet, Laia ^e   Majem, Margarita ^f   Bosch Barrera, Joaquim ^g   Porta, Rut ^g,h   Alonso, Nieves ⁱ   Palmero, Ramón ^j   Taus, Álvaro ^a   Albanell, Joan ^a   Espinet, Blanca ^a   Salido, Marta ^a   Arriola, Edurne ^a   more..

^a HOSPITAL DEL MAR   (Spain)

^b UNIVERSITAT POMPEU FABRA   (Spain)

^c HOSPITAL DE MATARÓ   (Spain)

^d HOSPITAL CLÍNIC   (Spain)

^e HOSPITAL LLUÍS ALCANYÍS   (Spain)

^f HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^g HOSPITAL JOSEP TRUETA   (Spain)

^h UNIVERSITY OF GIRONA   (Spain)

ⁱ Pathology Department   (Spain)

^j HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

more..

Author keywords

ALK; Biopsy; Cytology; FISH; Non small cell lung cancer

Indexed keywords

ADULT; ANAPLASTIC LYMPHOMA KINASE GENE; ARTICLE; CANCER STAGING; CLINICAL FEATURE; CORRELATION ANALYSIS; CYTOLOGY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE; GENE DOSAGE; HISTOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; NON SMALL CELL LUNG CANCER; PRIORITY JOURNAL; SPAIN; ENZYMOLOGY; GENE REARRANGEMENT; GENETICS; LUNG TUMOR; PATHOLOGY; PROCEDURES; RETROSPECTIVE STUDY;

ANAPLASTIC LYMPHOMA KINASE; PROTEIN TYROSINE KINASE;

CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; GENE REARRANGEMENT; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; RECEPTOR PROTEIN-TYROSINE KINASES; RETROSPECTIVE STUDIES;

EID: 84927594469     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0000000000000361     Document Type: Article

References (23)

1. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014;64:9-29.
2. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004;350:2129-2139.
3. Davies KD, Le AT, Theodoro MF, et al. Identifying and targeting ROS1 gene fusions in non-small cell lung cancer. Clin Cancer Res 2012;18:4570-4579.
4. Slebos RJ, Kibbelaar RE, Dalesio O, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990;323:561-565.
5. Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007;448:561-566.
6. Chiarle R, Voena C, Ambrogio C, Piva R, Inghirami G. The anaplastic lymphoma kinase in the pathogenesis of cancer. Nat Rev Cancer 2008;8:11-23.
7. Takeuchi K, Choi YL, Togashi Y, et al. KIF5B-ALK, a novel fusion oncokinase identified by an immunohistochemistry-based diagnostic system for ALK-positive lung cancer. Clin Cancer Res 2009;15:3143-3149.
8. Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007;131:1190-1203.
9. Hong M, Kim RN, Song JY, et al. HIP1-ALK, a novel fusion protein identified in lung adenocarcinoma. J Thorac Oncol 2014;9:419-422.
10. Choi YL, Lira ME, Hong M, et al. A novel fusion of TPR and ALK in lung adenocarcinoma. J Thorac Oncol 2014;9:563-566.
11. Salido M, Pijuan L, Martínez-Avilés L, et al. Increased ALK gene copy number and amplification are frequent in non-small cell lung cancer. J Thorac Oncol 2011;6:21-27.
12. Camidge DR, Bang YJ, Kwak EL, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012;13:1011-1019.
13. Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363:1693-1703.
14. Riccio A, Li Y, Moon J, et al. Essential role for TRPC5 in amygdala function and fear-related behavior. Cell 2009;137:761-772.
15. Ren S, Hirsch FR, Varella-Garcia M, et al. Atypical negative ALK breakapart FISH harboring a crizotinib-responsive ALK rearrangement in nonsmallcell lung cancer. J Thorac Oncol 2014;9:e21-e23.
16. Savic S, Bubendorf L. Role of fluorescence in situ hybridization in lung cancer cytology. Acta Cytol 2012;56:611-621.
17. Schiller JH, Harrington D, Belani CP, et al.; Eastern Cooperative Oncology Group. Comparison of four chemotherapy regimens for advanced nonsmallcell lung cancer. N Engl J Med 2002;346:92-98.
18. Thunnissen E, Bubendorf L, Dietel M, et al. EML4-ALK testing in non-small cell carcinomas of the lung: a review with recommendations. Virchows Arch 2012;461:245-257.
19. Yang J, Bielenberg DR, Rodig SJ, Doiron R, Clifton MC, Kung AL, et al. Lipocalin 2 promotes breast cancer progression. Proc Natl Acad Sci U S A [Research Support, N. I. H., Extramural Research Support, Non-U. S. Gov't]. 2009;106:3913-3918.
20. Shaw AT, Yeap BY, Mino-Kenudson M, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009;27:4247-4253.
21. Cabillic F, Gros A, Dugay F, et al. Parallel FISH and immunohistochemical studies of ALK status in 3244 non-small-cell lung cancers reveal major discordances. J Thorac Oncol 2014;9:295-306.
22. Rodig SJ, Mino-Kenudson M, Dacic S, et al. Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population. Clin Cancer Res 2009;15:5216-5223.
23. Wallander ML, Geiersbach KB, Tripp SR, Layfield LJ. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing. Arch Pathol Lab Med 2012;136:796-803.